- Home
- MDGL vs BXP Comparison
MDGL vs BXP Comparison
Compare MDGL & BXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | BXP |
|---|---|---|
| Founded | 2011 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 9.4B |
| IPO Year | 2005 | 1999 |
Fundamental Metrics
Financial Performance| Metric | MDGL | BXP |
|---|---|---|
| Price | $486.83 | $60.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 18 |
| Target Price | ★ $674.45 | $71.94 |
| AVG Volume (30 Days) | 284.2K | ★ 1.2M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.86% |
| EPS Growth | 41.32 | ★ 1833.33 |
| EPS | N/A | ★ 0.64 |
| Revenue | $180,133,000.00 | ★ $3,482,279,000.00 |
| Revenue This Year | $58.39 | $11.00 |
| Revenue Next Year | $48.55 | $2.91 |
| P/E Ratio | ★ N/A | $95.16 |
| Revenue Growth | N/A | ★ 2.19 |
| 52 Week Low | $275.00 | $49.93 |
| 52 Week High | $615.00 | $79.33 |
Technical Indicators
Market Signals| Indicator | MDGL | BXP |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 61.43 |
| Support Level | $461.99 | $57.41 |
| Resistance Level | $502.97 | $62.50 |
| Average True Range (ATR) | 21.60 | 1.41 |
| MACD | -6.10 | -0.01 |
| Stochastic Oscillator | 37.40 | 93.18 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About BXP Boston Properties Inc.
BXP owns 179 properties consisting of approximately 52.6 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.